FOOD AND DRUG ADMINISTRATION
Center for Drug Evaluation and Research
ANTI-INFECTIVE DRUGS ADVISORY COMMITTEE (AIDAC) MEETING
QUESTIONS TO THE COMMITTEE
January 8, 2003
Marriott Washingtonian Center, Grand Ballroom, 9751 Washingtonian Blvd., Gaithersburg, MD
NDA 21-144, Ketek™ (telithromycin), Aventis Pharmaceuticals, Inc., proposed for treatment of community-acquired pneumonia, acute exacerbation of chronic bronchitis, and acute maxillary sinusitis
If yes, are there any special caveats that should be included in the label?
If no, what other information would be required?
If yes, are there any special caveats that should be included in the label?
If no, what other information would be required?
If yes, are there any special caveats that should be included in the label?
If no, what other information would be required?